EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 12 (2026) SICOT-J, 12 (2026) 2 References
Open Access
Review
Issue
SICOT-J
Volume 12, 2026
Article Number 2
Number of page(s) 9
Section Knee
DOI https://doi.org/10.1051/sicotj/2025063
Published online 22 January 2026
  1. Flanagan AM, Larousserie F, O’Donnell PG, Yoshida A (2020) Giant cell tumour of bone. In WHO classification of tumours, 5th edn., soft tissue and bone, Lyon, International Arctic Research Center. [Google Scholar]
  2. Tabarestani TQ, Levine N, Sachs E, et al. (2023) Giant cell tumor of bone in the pediatric population: a retrospective study highlighting cases of metaphyseal only location and increased local recurrence rates in skeletally immature patients. Skeletal Radiol 52, 2399–2408. [Google Scholar]
  3. Tsukamoto S, Mavrogenis AF, Tanzi P, et al. (2019) Similar local recurrence but better function with curettage versus resection for bone giant cell tumor and pathological fracture at presentation. J Surg Oncol 119, 864–872. [Google Scholar]
  4. Chawla S, Henshaw R, Seeger L, et al. (2013) Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 14, 901–908. [Google Scholar]
  5. Rutkowski P, Ferrari S, Grimer RJ, et al. (2015) Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol 22, 2860–2868. [Google Scholar]
  6. Errani C, Tsukamoto S, Leone G, et al. (2018) Denosumab may increase the risk of local recurrence in patients with giant-cell tumor of bone treated with curettage. J Bone Joint Surg Am 100, 496–504. [Google Scholar]
  7. Tsukamoto S, Tanaka Y, Mavrogenis AF, et al. (2020) Is treatment with denosumab associated with local recurrence in patients with giant cell tumor of bone treated with curettage? A systematic review. Clin Orthop Relat Res 478, 1076–1085. [Google Scholar]
  8. Mak IWY, Evaniew N, Popovic S, et al. (2014) A translational study of the neoplastic cells of giant cell tumor of bone following neoadjuvant denosumab. J Bone Joint Surg Am 96, e127. [Google Scholar]
  9. Traub F, Singh J, Dickson BC, et al. (2016) Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone. Eur J Cancer 59, 1–12. [Google Scholar]
  10. Agarwal MG, Gundavda MK, Gupta R, Reddy R (2018) Does denosumab change the giant cell tumor treatment strategy? Lessons learned from early experience. Clin Orthop Relat Res 476, 1773–1782. [Google Scholar]
  11. Scoccianti G, Totti F, Scorianz M, et al. (2018) Preoperative denosumab with curettage and cryotherapy in giant cell tumor of bone: Is there an increased risk of local recurrence? Clin Orthop Relat Res 476, 1783–1790. [CrossRef] [PubMed] [Google Scholar]
  12. Yang Y, Li Y, Liu W, et al. (2018) A nonrandomized controlled study of sacral giant cell tumors with preoperative treatment of denosumab. Med (Baltimore) 97, e13139. [Google Scholar]
  13. Medellin MR, Fujiwara T, Tillman RM, et al. (2018) Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture. Bone Joint J 100-B, 1626–1632. [Google Scholar]
  14. Asano N, Saito M, Kobayashi E, et al. (2022) Preoperative denosumab therapy against giant cell tumor of bone is associated with an increased risk of local recurrence after curettage surgery. Ann Surg Oncol 29, 3992–4000. [Google Scholar]
  15. Tsukamoto S, Hindiskere S, Honoki K, et al. (2023) Outcome of re-operation for local recurrence following pre-operative denosumab administration and curettage for giant cell tumour of bone with difficult joint preservation. Int Orthop 47, 265–273. [Google Scholar]
  16. Jiang X, Chen J, Zhou W, et al. (2023) Microwave in situ inactivation in the treatment of bone giant cell tumor: a mid-term descriptive study. J Cancer Res Clin Oncol 149, 4653–4661. [Google Scholar]
  17. Moore C, Fernandes RJ, Manrique J, et al. (2022) Cytotoxic effects of common irrigation solutions on chondrosarcoma and giant cell tumors of bone. J Bone Joint Surg Am 104, 2153–2159. [Google Scholar]
  18. Tan L, Li Y, Hu X, et al. (2023) Clinical evaluation of the three-dimensional printed strut-type prosthesis combined with autograft reconstruction for giant cell tumor of the distal femur. Front Oncol 13, 1206765. [Google Scholar]
  19. Arrigoni F, Zoccali C, Evangelista L, et al. (2023) CT-guided RFA for management of surgical relapses of giant cell tumour of bone. Cardiovasc Intervent Radiol 46, 508–511. [Google Scholar]
  20. Toda Y, Ogura K, Iwata S, et al. (2024) The diagnostic and prognostic value of tartrate-resistant acid phosphatase isoform 5b for giant cell tumor of bone. Int J Clin Oncol 29, 1391–1397. [Google Scholar]
  21. Xu H, Zhou Y, Liang L, et al. (2024) Efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone: a multicenter, phase Ib/II study. Nat Commun 15, 9541. [Google Scholar]
  22. Errani C, Ruggieri P, Asenzio MAN, et al. (2010) Giant cell tumor of the extremity: A review of 349 cases from a single institution. Cancer Treat Rev 36, 1–7. [Google Scholar]
  23. Machak GN, Snetkov AI (2021) The impact of curettage technique on local control in giant cell tumour of bone. Int Orthop 45, 779–789. [Google Scholar]
  24. Zheng K, Yu X, Hu Y, et al. (2020) Clinical guideline for microwave ablation of bone tumors in extremities. Orthop Surg 12, 1036–1044. [Google Scholar]
  25. Bombardier B, Haase D, Sweeney K, et al. (2021) A comparison of depth of necrosis among adjuvant therapies used for the treatment of benign bone tumors. J Surg Oncol 123, 1299–1303. [Google Scholar]
  26. Wang Y, Shao P, Tian Q, et al. (2023) “Triple clear”: a systematic and comprehensive surgical process for Campanacci grades II and III giant cell tumors of the bone, with or without pathological fracture and slight joint invasion. World J Surg Oncol 21, 114. [Google Scholar]
  27. Furuta T, Kubo T, Sakuda T, et al. (2022) Utility of intraoperative magnetic resonance imaging for giant cell tumor of bone after denosumab treatment: a pilot study. Acta Radiol 63, 176–181. [Google Scholar]
  28. Zhou L, Zhu H, Lin S, et al. (2022) Computerised tomography features of giant cell tumour of the knee are associated with local recurrence after extended curettage. Int Orthop 46, 381–390. [Google Scholar]
  29. Benevenia J, Rivero SM, Moore J, et al. (2017) Supplemental bone grafting in giant cell tumor of the extremity reduces nononcologic complications. Clin Orthop Relat Res 475, 776–783. [Google Scholar]
  30. Teng W, Lin P, Li Y, et al. (2018) Bone combined cement grafting in giant cell tumor around the knee reduces mechanical failure. Int Orthop 43(2), 475–482. [Google Scholar]
  31. Hisatome T, Yasunaga Y, Ikuta Y, Fujimoto Y (2002) Effects on articular cartilage of subchondral replacement with polymethylmethacrylate and calcium phosphate cement. J Biomed Mater Res 59, 490–498. [Google Scholar]
  32. Murray PJ, Damron TA, Green JK, et al. (2004) Contained femoral defects: biomechanical analysis of pin augmentation in cement. Clin Orthop Relat Res 420, 251–256. [Google Scholar]
  33. Welch RD, Berry BH, Crawford K, et al. (2002) Subchondral defects in caprine femora augmented with in situ setting hydroxyapatite cement, polymethylmethacrylate, or autogenous bone graft: biomechanical and histomorphological analysis after two-years. J Orthop Res 20, 464–472. [Google Scholar]
  34. Takeuchi A, Suwanpramote P, Yamamoto N, et al. (2018) Mid- to long-term clinical outcome of giant cell tumor of bone treated with calcium phosphate cement following thorough curettage and phenolization. J Surg Oncol 117, 1232–1238. [Google Scholar]
  35. Errani C, Tsukamoto S, Ciani G, Donati DM (2019) Present day controversies and consensus in curettage for giant cell tumor of bone. J Clin Orthop Trauma 10, 1015–1020. [Google Scholar]
  36. López-Vidaur Franco I, Bueno Horcajadas A, Martel Villagrán J, Ortiz Cruz E (2024) Percutaneous radiofrecuency thermal ablation for management of recurrent bone giant cell tumour. Quant Imaging Med Surg 14, 8050–8057. [Google Scholar]
  37. Shinozaki T, Saito K, Kobayashi T, et al. (2012) Tartrate-resistant acid phosphatase 5b is a useful serum marker for diagnosis and recurrence detection of giant cell tumor of bone. Open Orthop J 6, 392–399. [Google Scholar]
  38. Costelloe CM, Kumar R, Yasko AW, et al. (2007) Imaging characteristics of locally recurrent tumors of bone. AJR Am J Roentgenol 188, 855–863. [Google Scholar]
  39. Liu F, Zhao J, Xie J, et al. (2016) Prognostic risk factors in patients with bone metastasis from colorectal cancer. Tumour Biol 37, 16127–16134. [Google Scholar]
  40. Lim SM, Kim YN, Park KH, et al. (2016) Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. BMC Cancer 16, 385. [Google Scholar]
  41. Huang P, Lan M, Peng AF, et al. (2017) Serum calcium, alkaline phosphotase and hemoglobin as risk factors for bone metastases in bladder cancer. PLoS One 12, e0183835. [Google Scholar]
  42. Ren HY, Sun LL, Li HY, Ye ZM (2015) Prognostic significance of serum alkaline phosphatase level in osteosarcoma: A meta-analysis of published data. Biomed Res Int 2015, 160835. [Google Scholar]
  43. Tsukamoto S, Mavrogenis AF, Alvarado RA, et al. (2023) Association between inflammatory markers and local recurrence in patients with giant cell tumor of bone: A preliminary result. Curr Oncol 30, 1116–1131. [Google Scholar]
  44. Zhou L, Zuo D, Wen J, et al. Reduced recurrence rate and comparable functionality after wide resection and reverse total shoulder arthroplasty with allograft-prosthetic composite versus curettage for proximal humeral giant cell tumor: a multicenter retrospective study. J Shoulder Elbow Surg 33, 1040–1049. [Google Scholar]
  45. Chawla S, Blay J-Y, Rutkowski P, et al. (2019) Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol 20, 1719–1729. [CrossRef] [PubMed] [Google Scholar]
  46. Jiang CY, Zhao L, Schuetze SM, Chugh R (2022) Giant cell tumor of bone: Effect of longer dosing intervals of denosumab on tumor control and bone-related complications. Oncologist 27, 595–599. [Google Scholar]
  47. Nakata E, Kunisada T, Fujiwara T, et al. (2024) Efficacy and safety of denosumab de‑escalation in giant cell tumor of bone. Oncol Lett 28, 387. [Google Scholar]
  48. Thornley P, Habib A, Bozzo A, et al. (2017) The role of denosumab in the modern treatment of giant cell tumor of bone. JBJS Rev 5, e4. [Google Scholar]
  49. Formica VM, Bruno V, Uccio ASD, et al. (2023) The giant cell tumor during pregnancy: a review of literature. Orthop Traumatol Surg Res 109, 103396. [Google Scholar]
  50. Machak GN, Bruland ØS, Romanova TN, Kovalev AV (2024) Denosumab induction and Zoledronic acid maintenance therapy for recurrent unresectable giant cell tumour of the distal tibia: A case report with sustained tumour control after drug withdrawal. J Bone Oncol 45, 100596. [Google Scholar]
  51. Dillon TM, Ricci MS, Vezina C, et al. (2008) Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 283, 16206–16215. [Google Scholar]
  52. Wypych J, Li M, Guo A, et al. (2008) Human IgG2 antibodies display disulfide-mediated structural isoforms. J Biol Chem 283, 16194–16205. [Google Scholar]
  53. Wang X, Kumar S, Singh SK (2011) Disulfide scrambling in IgG2 monoclonal antibodies: insights from molecular dynamics simulations. Pharm Res 28, 3128–3144. [Google Scholar]
  54. Yu J, Song Y, Tian W (2020) How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J Hematol Oncol 13, 45. [Google Scholar]
  55. Liang X, Xue J, Ge X, et al. (2022) Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors. Front Oncol 12, 971594. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.